Lenvervimab

Lenvervimab
Monoclonal antibody
Type	?
Source	Humanized
Target	hepatitis B virus surface antigen
Clinical data
Other names	GC1102
ATC code	none;
Identifiers
CAS Number	2055006-79-4 ;
UNII	FX9X4L2A2L ;

Last updated September 30, 2025

Lenvervimab (INN;^[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.^[2]

This drug is being developed by GC Pharma. As of 2018^[update], lenvervimab is undergoing Phase II/III trials.

References

↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
↑ Jeong GU, Ahn BY, Jung J, Kim H, Kim TH, Kim W, Lee A, Lee K, Kim JH (2020). "A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants". PLOS ONE. 15 (8) e0236704. Bibcode:2020PLoSO..1536704J. doi: 10.1371/journal.pone.0236704 . PMC 7425877 . PMID 32790777.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[WHOList118-1] World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).

[pmid32790777-2] Jeong GU, Ahn BY, Jung J, Kim H, Kim TH, Kim W, Lee A, Lee K, Kim JH (2020). "A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants". PLOS ONE. 15 (8) e0236704. Bibcode:2020PLoSO..1536704J. doi: 10.1371/journal.pone.0236704 . PMC 7425877 . PMID 32790777.

[1]

[2]